A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD)

← catalyst calendar

NCT07768592 · readout in 1,355 d

Sponsored by Eisai Inc. (industry) · 4523.T — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

32estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-10-15

estimated

When the study began enrolling

Primary completion

2030-05-06

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-05-06

estimated

The whole study's end, after follow-up

First posted

2026-08-17

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Alzheimers Disease

Interventions

Drug: E2511
Drug: Donepezil — also filed as Aricept

Primary outcomes

what the primary-completion date above is the date OF

Part A (Core Trial): Change from Baseline in [11C]MK-6884 Positron Emission Tomography (PET) Using Non-Displaceable Binding Potential (BPND) at 14 Days

measured Baseline up to Day 14

Part A and B (Extension Phase): Number of Participants With Adverse Events (AEs)

measured Up to 91 weeks

Part A and B (Extension Phase): Number of Participants With Clinically Significant Changes in Vital Sign Values